Absci Corporation
ABSI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ABSI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ABSI
Absci Corporation is a clinical-stage biopharmaceutical company leveraging generative AI and its Integrated Drug Creation platform to develop antibody therapeutics for conditions with limited treatment options, including alopecia areata and endometriosis.
Key risk: Clinical development risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.49B
Cash Runway
21.7 moLead Asset
ABS-201 (Preclinical)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 catalysts for Absci Corporation.
Absci Corporation is a clinical-stage biopharmaceutical company leveraging generative AI and its Integrated Drug Creation platform to develop antibody therapeutics for conditions with limited treatment options, including alopecia areata and endometriosis.
- Absci is a clinical-stage biopharmaceutical company advancing potential breakthrough antibody therapeutics with generative AI [sec_mda · as of 2025-11-12].
- As of June 30, 2026, the company reported cash & equivalents of $108.9M, total revenue of $0.3M, and a net loss of -$33.2M [sec].
- The company's accumulated deficit was $654.4 million as of March 31, 2026 [sec_mda · as of 2026-05-07].
- Interim proof-of-concept data for ABS-201 in alopecia areata are expected in the second half of 2026 [sec_mda · as of 2026-03-24].
- Absci plans to initiate a Phase 2 clinical trial of ABS-201 in endometriosis, a condition with no FDA-approved disease-modifying therapy [sec_mda · as of 2026-03-24].
What works
- Absci's Integrated Drug Creation platform uses generative AI to design antibody therapeutics, potentially enabling discovery against hard-to-drug targets [sec_mda · as of 2025-11-12].
- The company has multiple internally developed programs, including ABS-101 and ABS-201, with potential proof-of-concept data expected by the second half of 2026 [sec_mda · as of 2025-08-12].
- Absci believes its cash, cash equivalents, and marketable securities will be sufficient to meet operating expenses for at least the next 12 months as of May 2026 [sec_mda · as of 2026-05-07].
What to weigh
- Absci has incurred net operating losses since inception, with an accumulated deficit of $654.4 million as of March 31, 2026 [sec_mda · as of 2026-05-07].
- The company's future capital requirements depend on its ability to raise additional capital through equity or debt financing, which is uncertain [sec_mda · as of 2026-05-07].
- Absci's internally developed programs are still in clinical stages, and there is no guarantee of successful development or commercialization [sec_mda · as of 2025-11-12].
From the filings
Quoted directly from source documents.
Absci uses generative AI for antibody therapeutics
“Our Integrated Drug Creation platform comprises, in part, cutting edge generative AI models aimed at designing better antibody therapeutics, including against hard-to-drug targets.”
SEC MD&A · November 12, 2025
Accumulated deficit as of March 31, 2026
“As of March 31, 2026, our accumulated deficit was $654.4 million.”
SEC MD&A · May 7, 2026
Interim proof-of-concept data for ABS-201 expected in H2 2026
“Interim proof-of-concept data, including exploratory efficacy endpoints, are expected in the second half of 2026.”
SEC MD&A · March 24, 2026
No FDA-approved disease-modifying therapy for endometriosis
“There is currently no FDA-approved disease-modifying therapy for endometriosis.”
SEC MD&A · March 24, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · abs-201 — Phase 2 Readout: abs-201 — Topline data from the Phase 2 trial of ABS-201 are expected, which could provide proof-of-concept for the program.
- 2026-12-31 · Phase2_Topline — Phase 2 Readout: pipeline candidate — A Phase 2 readout for a pipeline candidate is anticipated, representing a key clinical milestone.
Risks & what to watch (3)›
Key risks
- Clinical development risk — ABS-201 and other pipeline candidates are in early stages; failure in trials could halt programs [sec_mda · as of 2025-11-12].
- Capital needs and dilution — Absci has a history of losses and may need additional financing, which could dilute shareholders [sec_mda · as of 2026-05-07].
- Platform adoption uncertainty — Driving adoption of the Integrated Drug Creation platform requires significant investment and may not succeed [sec_mda · as of 2025-08-12].
What to watch
- Interim proof-of-concept data for ABS-201 in alopecia areata expected in the second half of 2026 [sec_mda · as of 2026-03-24].
- Initiation of Phase 2 clinical trial for ABS-201 in endometriosis [sec_mda · as of 2026-03-24].
- Progress of ABS-101 Phase 1 clinical trial for Inflammatory Bowel Disease, initiated in May 2025 [sec_mda · as of 2025-08-12].
- Ability to raise additional capital and manage cash runway beyond the next 12 months [sec_mda · as of 2026-05-07].
Sources: SEC MD&A · Generated August 12, 2026 · How we verify sources →
Run Absci Corporation through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Absci Corporation facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
21.7 months
D/E 0.09 · 0% dilution
Lead: Preclinical
1 candidate
2 upcoming, next in ~123d
3 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
162
Total value held
$347.3M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 22,550,997 | $67.7M |
| ark investment management llc | 13,726,169 | $41.2M |
| blackrock, inc. | 11,255,194 | $33.8M |
| state street corp | 7,324,858 | $22.0M |
| vanguard capital management llc | 5,886,640 | $17.7M |
| advanced micro devices inc | 5,714,285 | $17.1M |
| geode capital management, llc | 3,343,068 | $10.0M |
| ameriprise financial inc | 3,180,141 | $9.5M |
| two sigma investments, lp | 2,898,766 | $8.7M |
| gem investment advisors, llc | 2,170,863 | $6.5M |
Showing top 10 of 162 institutional holders of Absci Corporation. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 28.6%
- Days to cover
- 8.7
- Shares short
- 37,328,959
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ABSI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Absci Corporation?
Absci Corporation is a clinical-stage biopharmaceutical company leveraging generative AI and its Integrated Drug Creation platform to develop antibody therapeutics for conditions with limited treatment options, including alopecia areata and endometriosis.
What is Absci Corporation's lead drug candidate?
Absci Corporation's most advanced tracked candidate is ABS-201 (Preclinical) for Endometriosis.
What is Absci Corporation's next catalyst?
Absci Corporation's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: abs-201" — expected December 31, 2026.
Who is the CEO of Absci Corporation?
Mr. Sean McClain is the chief executive officer of Absci Corporation (ABSI).
Where is Absci Corporation headquartered?
Absci Corporation (ABSI) is headquartered in Vancouver, WA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.